Ebola Drug Cures COVID-19 Patient

Clinical trials and compassionate use permission underway

Ebola drug cured COVID-19 patient

Ebola drug cured COVID-19 patient

A new experimental drug called Remdesivir has cured the first community-spread COVID-19 patient in California to be stricken with the coronavirus. The patient had not traveled to another country, and the source of her infection is not known. The results were confirmed in an interview with Science by Dr. George Thompson, an infectious disease specialist at the University of California Davis Medical Center in Sacramento, who was one of the doctors treating the patient who has been identified as a female.

Upon realizing she was near death, the doctors secured compassionate use permission from the Food and Drug Administration to test Remdesivir, which is manufactured by Gilead Sciences, and delivered via intravenous drip. It can have side effects including nausea, vomiting, rectal bleeding, and elevated liver enzymes.

The drug is not known to specifically target COVID-19. Instead, it interferes with RNA polymerases, which various kinds of pathogenic viruses use to replicate themselves after hijacking host cells. It has also been shown to be experimentally effective against SARS-CoV-2 (severe acute respiratory syndrome) and Middle East respiratory syndrome, both conroaviruses with some 80% similarity to COVID-19. (However, the drug didn’t work when tested in the Democratic Republic of the Congo against Ebola.)

comments powered by Disqus